HLA-C and cancer: Tebentafusp not only serves as the harbinger for fbAb and TCE development in treating solid tumors but also paved the way for developing antibody therapies against MHC-peptide complexes as well as neoantigen therapy, a promising avenue for curing even the most recalcitrant types of cancer.